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Abstract
Background Cardiac allograft vasculopathy (CAV) is a mul-
tifactorial disease and a major cause of graft failure after
heart transplantation. However, the impact of CAV may
vary according to the definition and the regional differences
in transplantation settings.
Objectives We sought to assess CAV prevalence, predictors
and prognosis in Dutch heart transplant recipients based on
coronary angiography, following the 2010 standard nomen-
clature of the International Society for Heart and Lung
Transplantation.
Methods Patients ≥18 years who underwent heart trans-
plantation at our centre with at least one coronary angiog-
raphy during follow-up were included in the analysis. Clin-
ical variables were collected prospectively.
Results Among 495 analysed recipients, there were 238
(48 %) with CAV. The prevalence of CAV was 18, 47 and
70 % at 4, 12 and 20 years, respectively. In the multivariable
proportional hazards regression analysis, only male donor
gender and increasing donor age were significantly associ-
ated with the risk of CAV. The long-term prognosis of the
patients with CAV at fourth-year angiography was signifi-
cantly worse as compared with that of CAV-free patients,
independently of the severity of CAV (p < 0.001).
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Conclusion The prevalence of CAV increased gradually
over time, with a similar trend as in other registries. Post-
transplant survival is decreased in patients with any degree
of early CAV, indicating that management strategies should
start with donor selection and preventive measures imme-
diately after transplantation.
Keywords Cardiac allograft vasculopathy (CAV) · Donor
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Introduction
Cardiac allograft vasculopathy (CAV) is one of the major
causes of late graft failure and death in heart transplant pa-
tients [1]. The reported CAV prevalence varies according
to the definition, population, transplantation period and fol-
low-up protocol and ranges from 39 to 65 % at 10 years
in single-centre studies, while in the large register of the
International Society for Heart and Lung Transplantation
(ISHLT) it is 50 % at 10 years [1–3]. CAV is characterised
by concentric thickening of the wall of large and small coro-
nary vessels and has various histological patterns, including
inflammatory lesions, lesions rich in smooth muscle cells
and fibrotic lesions, which have been related to the time
passing after transplantation [4, 5]. The pathogenesis of
CAV has been related to immunological and non-immuno-
logical factors in both the donor and the recipient, but the
exact triggers and the pathophysiological pathways are still
unknown [6, 7]. The data are heterogeneous due to different
transplantation decades, different populations and treatment
protocols and their generalisability is further hampered by
various diagnostic criteria of CAV [6, 8]. Standardisation
of the CAV diagnosis and gradation was recommended in
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2010 by the ISHLT based on conventional coronary angiog-
raphy [9].
In the Netherlands, the shortage of the donors has led
to an increase in the mean donor age from 29 to 43 years,
while the most frequent cause of death shifted from trauma
to stroke. Despite the use of older donors, we found an im-
proved survival after heart transplantation in the last decade
at our centre [10]. However, subclinical atherosclerosis may
be more frequent in donor hearts from older patients with
neurovascular comorbidity and, therefore, the first aim of
the current study was to investigate CAV prevalence and
predictors in the patients undergoing heart transplantation
in the Netherlands, using our large single-centre cohort.
Secondly, we aimed to assess the long-term prognosis tak-
ing into account the diagnosis and severity of CAV.
Patients and methods
Study population
Since the first orthotopic heart transplantation at our centre
in June 1984, data of all heart transplant recipients were
collected prospectively until December 2012. Patients con-
sented to the use of anonymised data for research purposes.
The institutional review board of the Erasmus MC approved
the present study.
Only patients ≥18 years who underwent at least one con-
ventional coronary angiography at follow-up were included
in the analysis. We recorded recipient-related and donor-
related variables based on the clinical relevance and previ-
ously published studies on CAV predictors. Recipient pre-
transplant clinical variables were age, gender, aetiology of
heart failure, creatinine and diabetes. Donor-related data
were age, gender and cause of death. Donor-recipient mis-
match variables and available immunological information
were collected. Data at one year after transplantation in-
cluded the number of acute rejection episodes, development
of cytomegalovirus-related disease, serum creatinine, total
cholesterol, triglycerides, diagnosis of hypertension and di-
abetes. Rejection surveillance was based on endomyocar-
dial biopsies, which were graded according to the Billing-
ham’s criteria until 2004 [11, 12] and subsequently accord-
ing to the ISHLT revised guidelines [13]. Acute rejections
were defined as the treated rejections within the first year
after transplantation in each patient. Immunosuppressive
medication and the use of statins were recorded at the time
of CAV diagnosis or at the time of the most recent angiog-
raphy for the patients without CAV. Mortality and retrans-
plantation were recorded as outcome events.
Diagnosis of CAV
Coronary angiography (CAG) was performed per protocol
every year until 1990. After 1990, CAG was performed
at one year and repeated every year in case of evidence
of CAV, otherwise postponed to the fourth year after
transplantation [14]. After the fourth year post-transplanta-
tion, patients underwent non-invasive myocardial perfusion
scintigraphy annually for assessment of ischaemia. CAG
was performed in these patients when perfusion scintigra-
phy was positive, or when ischaemia was suspected based
on cardiac markers or clinical, electrocardiographic or
echocardiographic criteria. Two cardiologists reviewed all
the available coronary angiographies, or, when the CAG
images were absent in our archive, the diagnosis of CAV
was made from the written report and re-graded according
to the 2010 ISHLT criteria [9]. In summary, CAV grade 1
applies to stenosis <70 % of primary or secondary coronary
branches, CAV grade 2 applies to stenosis ≥70 % of one
primary branch or two secondary branches, CAV grade 3
applies to stenosis ≥70 % of two primary branches or three
secondary branches, or if an impaired left ventricular func-
tion is associated with any degree of CAV. For each patient
we recorded the time from heart transplant until the first
CAG showing any degree of CAV.
Statistical analysis
For the analysis of CAV prevalence, the proportion of pa-
tients with CAV among survivors was calculated at pre-
defined points, i. e. at 1, 4, 8, 12, 16 and 20 years post-
transplantation. Donor and recipient variables were com-
pared between CAV-free and CAV patients. Categorical
data are presented as numbers with percentages. Continu-
ous data are presented as mean ± standard deviation. The
data were compared using the chi-square test for categori-
cal variables, and independent sample t-test for continuous
variables. Univariate analysis of donor and recipient char-
acteristics was performed using the Cox proportional haz-
ards model. Significant results from the univariate analysis
(p  0.05), but also non-significant clinically relevant vari-
ables were included in the multivariable proportional haz-
ards regression analysis using the backward procedure. For
survival analysis, the outcome was the combination of all-
cause mortality and retransplantation according to the pres-
ence or absence of CAV using the Kaplan-Meier method
and the log-rank test for comparison. Data were analysed
using IBM SPSS Statistics version 21.
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Fig. 1 Flowchart study popula-
tion
Table 1 Detection of CAV after heart transplantation
N (%)
Mean follow-up 10.6 ± 5.7 years
N. patients with CAV diagnosis 238 (48.1)
Time to CAV after heart transplantation
Median
Range
6.1 ± 4.2 years
4.9 years
17 days–18 years
CAV grade at diagnosis
1
2
3
–
143 (60.1)
65 (27.3)
30 (12.6)
Results
From the cohort of 612 heart transplant recipients, 495 were
included in the analysis (Fig. 1). The mean age at trans-
plantation was 48.6 ± 10.3 years, and 77.4 % of recipients
were males. Ischaemic heart disease was the cause of heart
failure before transplantation in 49.9 % of the patients. Di-
abetes was present in 6.1 % of the patients before transplan-
tation. Mean donor age was 33.3 ± 12.9 years and 52.7 %
of the donors were males. The cause of death was trauma in
48.8 % of the donors. During the first year post-transplan-
tation, hypertension, diabetes and cytomegalovirus disease
were present in 75, 32 and 20 % of the patients, respec-
tively. At one year after transplantation only a minority of
the recipients (22.6 %) were free of any rejection episodes,
while 21.6 % had more than two rejection episodes.
Fig. 2 CAV prevalence in survivors after heart transplantation
A total of 238 (48.1 %) transplant recipients received the
diagnosis of CAV. Mean time to CAV detection was 6.1 ±
4.2 years after transplant, with the median at the fourth year
after transplantation, when CAG was routinely performed
according to the follow-up protocol. The majority of the
affected patients (60.1 %) had a mild CAV (grade 1), while
12.6 % of the patients had severe CAV (grade 3) at diagno-
sis (Table 1). The prevalence of CAV increased gradually
from 17.6 % at 4 years to 47 % at 12 years and 69.7 % at
20 years, while the number of surviving transplant recipi-
ents decreased during the follow-up period (Fig. 2).
The recipient characteristics before and after transplan-
tation, donor characteristics, immunosuppression and statin
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Fig. 3 Forest plot of risk factors
included in the multivariate Cox
proportional hazard modelling
Fig. 4 a Long-term survival in CAV versus CAV-free patients. Kaplan-Meier analysis used to compare survival of patients alive at four years,
grouped into patients with CAV diagnosis within the fourth year and CAV-free patients. Curves were compared with log-rank test. b Long-term
survival according to CAV severity at four years. Log-rank overall: p < 0.0001, while log-rank analysis between CAV1 versus CAV ≥2 was not
significant (p = 0.0656)
therapy were compared between the cohorts of patients with
CAV and without CAV (Table 2). a significant difference in
the recipient age at transplantation and the donor age was
seen between the two cohorts. There was a significantly
higher proportion of male donors and higher cholesterol
levels at one year in the CAV cohort as compared with the
CAV-free cohort. No significant difference was found in
the immunosuppression induction therapy or maintenance
immunosuppression or statins therapy at the moment of
CAV diagnosis, renal function or the presence of diabetes
between the two cohorts. There was a trend for a larger
proportion of patients without any rejection in the CAV-
free cohort as compared with the CAV cohort (p = 0.06).
In the multivariable proportional hazard regression anal-
ysis only male donor gender and donor age were signifi-
cantly associated with CAV, with a gradual increased hazard
risk of 1.5, 2.2 and 2.8 in the three consecutive groups of
donor age, while post-transplantation clinical factors were
not significant (Fig. 3). The treatment with mycophenolate
mofetil was associated with a significantly increased risk
(HR 1.4, p = 0.008) only in the univariate analysis, while
cytomegalovirus disease was associated with an increased
hazard risk for CAV (HR 1.3, p = 0.059), although not
significant, in the univariate analysis (Table 3).
The long-term outcome consisting of survival or retrans-
plantation was compared between the patients with CAV
of any degree at fourth-year angiography and the patients
with no CAV at the same evaluation (Fig. 4a). The patients
with CAV diagnosis had a significantly impaired progno-
sis as compared with CAV-free patients at the fourth year
after transplantation (p < 0.001). Also, significantly de-
creased long-term survival was found for the patients with
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Table 2 Donor and recipient variables in CAV-free and CAV-affected patients
CAV-free population,
Group I (n = 257), N (%)
CAV population,
Group II (n = 238), N (%)
p valuea
Recipient
Recipient age, years
18–39
40–49
50–59
≥60
49.7 ± 10.2
40 (15.6)
74 (28.8)
105 (40.9)
38 (14.8)
47.4 ± 10.3
46 (19.3)
74 (31.1)
97 (40.8)
21 (8.8)
0.01
0.18
Recipient gender: Male/Female 192/65 (74.7/25.3) 191/47 (80/19.7) 0.11
Previous ischaemic heart disease 120 (46.7) 127 (53.4) 0.14
Creatinine pre-heart transplantation (µmol/l) 121.2 ± 42.9 121.7 ± 51.6 0.92
Diabetes pre-heart transplantation 15 (5.8) 15 (6.4) 0.81
Donor
Donor age, years 32.1 ± 13.4 34.7 ± 12.3 0.03
12–29
30–39
40–49
≥50
122 (48.2)
54 (21.3)
43 (17)
34 (13.4)
89 (37.9)
58 (24.7)
59 (25.1)
29 (12.3)
0.06
Donor death for head trauma 110 (47.4) 105 (50.2) 0.53
Donor gender: male/female 121/134 (47.5/52.5) 140/96 (59.3/40.7) 0.01
Mismatches donor/recipient
Gender mismatch: donor/recipient 99 (38.8) 83 (35.2) 0.4
Cytomegalovirus serology mismatch 59 (23) 55 (23.1) 0.97
Toxoplasmosis serology mismatch 41 (16) 41 (17.2) 0.7
HLA antibodies mismatch 69 (28.2) 73 (31.9) 0.38
Surgery and medical therapy
Ischaemia time 170.5 ± 42.1 176.6 ± 45.7 0.12
Cyclosporine 145 (56.4) 147 (61.8) 0.23
Tacrolimus 112 (43.6) 89 (37.4) 0.16
Mycophenolate mofetil (plus tacrolimus) 65 (25.3) 65 (27.3) 0.61
Everolimus (plus tacrolimus) 7(2.7) 10 (4.2) 0.37
Statin 114 (44.5) 112 (47.1) 0.55
Immunosuppressive induction therapy 208 (80.9) 181 (76.1) 0.19
Parameters at one year after heart transplantation
Cholesterol (mmol/l) 6.4 ± 1.7 6.7 ±2 0.03
Triglycerides (mmol/l) 2.3 ± 1.1 2.3 ±1 0.89
Hypertension 190 (73.9) 181 (76.1) 0.59
Diabetes 84 (32.7) 76 (32.1) 0.88
Creatinine (µmol/l) 144.5 ± 79.6 135.4 ± 59.1 0.14
Cytomegalovirus disease (within first year) 45 (17.5) 55 (23.1) 0.12
Absence of rejection episodes 67 (26.1) 45 (18.9) 0.06
Total number of rejection episodes 1.7 ± 1.6 1.9 ± 1.6 0.13
All results are expressed as absolute numbers and percentages or mean ± standard deviation. P-values were obtained with Pearson’s chi-square
test or t-test for equality of means. HLA human leucocyte antigen
mild CAV (grade 1) when compared with CAV-free patients
and there was no difference in survival of the CAV grade 1
group when compared with more advanced grades of CAV
(Fig. 4b).
Discussion
Our study has several findings: 1) the prevalence of CAV
increased gradually during follow-up to 70 % of the sur-
vivors at 20 years; 2) donor-related factors were associated
with an increased risk of CAV and 3) all CAV severity
grades, including mild coronary lesions, at the fourth year
Neth Heart J (2016) 24:748–757 755
Table 3 Univariate Cox regression analysis of determinants of CAV
HR 95 % CI p value
Donor age (ref. age <40)
40–49 1.4 1.04 ± 2.01 0.03
50–59 2 1.40 ± 2.72 <0.0001
>60 2.2 1.45 ± 3.39 <0.0001
Recipient age (ref. age 18–30)
30–39 1.1 0.73 ± 1.52 0.79
40–49 1.1 0.76 ± 1.53 0.68
≥50 0.8 0.48 ± 1.35 0.42
Male gender of donor 1.3 0.97 ± 1.63 0.09
Male gender of recipient 1.2 0.89 ± 1.68 0.23
Donor death for trauma 1.2 0.92 ± 1.58 0.18
Previous ischaemic heart disease 1.3 0.98 ± 1.64 0.07
Creatinine pre-heart transplantation 1.0 1.00 ± 1.00 0.82
Diabetes pre-heart transplantation 1.3 0.75 ± 2.13 0.39
Ischaemia time 1 1.00 ± 1.00 0.77
Toxoplasmosis serology mismatch 1.1 0.82 ± 1.61 0.42
Cytomegalovirus serology mismatch 1.1 0.78 ± 1.42 0.74
Cytomegalovirus disease 1.3 0.99 ± 1.81 0.059
Absence of any episodes of rejection 0.8 0.57 ± 1.09 0.16
HLA antibodies mismatch 0.9 0.68 ± 1.19 0.47
Induction treatment 1.1 0.83 ± 1.51 0.47
Cyclosporine 0.9 0.69 ± 1.16 0.4
Tacrolimus 1.1 0.83 ± 1.41 0.55
Mycophenolate mofetil 1.4 1.11 ± 1.97 0.008
Everolimus 1.5 0.82 ± 2.20 0.18
Statin 1.1 0.82 ± 1.37 0.64
Triglycerides (at one year) 1 0.86 ± 1.09 0.6
Cholesterol (at one year) 1 0.96 ± 1.10 0.48
Diabetes (at one year) 0.9 0.72 ± 1.24 0.68
Creatinine (at one year) 1 1.00 ± 1.00 0.82
Hypertension (at one year) 0.9 0.65 ± 1.19 0.4
HLA human leucocyte antigen
after heart transplantation, are associated with a decreased
long-term survival.
Prevalence and predictors of CAV
Although the donors in the Netherlands may be older than
in other transplantation settings, CAV prevalence in our co-
hort was comparable with that presented in the most recent
report of the ISHLT [1]. However, the strongest CAV risk
factor in our study was older donor age. Donor age has
been previously reported to be associated with an increased
risk of CAV in the database of the United Network for
Organ Sharing (in the United States), as well as in Span-
ish heart transplant registries [15, 16]. We found that also
male donor sex was associated with an increased risk of
CAV, irrespective of the gender of the recipient. Other stud-
ies have shown that gender mismatch, particularly a male
recipient receiving a female donor heart, was associated
with decreased survival after transplantation, but the re-
ports are contradictory about its relationship with the risk
the CAV [17]. Although we did not collect data on donor
risk factors, older and male donors might reasonably have
higher rates of hypertension, dyslipidaemia and/or history
of smoking, conferring the higher chance of subclinical vas-
cular atherosclerosis that might be correlated to neo-intima
fibrosis in CAV. Furthermore, donor-derived immunological
factors have been reported to contribute to the development
of CAV in addition of recipient immunity [18].
We could not find any recipient-related independent pre-
dictors of CAV, although in the univariate analysis the risk
of CAV was significantly associated with the treatment with
mycophenolate mofetil, while cytomegalovirus disease had
a trend towards positive association with CAV. The role of
cytomegalovirus disease in the development of CAV has
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been extensively studied, and a positive association has not
always been found, but a recent Spanish report has shown
that cytomegalovirus disease and even asymptomatic vi-
raemia are associated with increased risk [3]. The possi-
ble explanations for the association between treatment with
mycophenolate mofetil and CAV in the univariate analy-
sis, but not in the multivariable analysis, could be an in-
creased susceptibility for cytomegalovirus disease during
mycophenolate mofetil treatment, or the need for increased
immunosuppression due to rejection episodes. Other stud-
ies have shown that high rejection scores or repeated acute
cardiac rejections are independent predictors of CAV [7,
19]. We did not find a significant association after Cox re-
gression analysis, although the number of patients without
any rejection episodes was higher in the CAV-free cohort as
compared with the CAV cohort. No other transplantation
treatment was found to be associated with CAV. The use
of statins has been associated with increased survival after
heart transplantation, and it is recommended in the guide-
lines for the care of heart transplant recipients [20]. One
possible explanation for the lack of a positive effect can
be the inclusion of patients transplanted before the statin
era in the analysis. The number of patients treated with
everolimus, as maintenance therapy before coronary an-
giography, was too low to assess its association with CAV.
Prognosis of CAV
We present the survival curves according to the presence of
CAV at four years after transplantation, because all patients
then underwent elective coronary angiography, according
to the protocol at our centre. After the fourth year, pa-
tients underwent myocardial perfusion scintigraphy yearly
for evaluation of ischaemia, and coronary angiography was
only performed by indication. An important finding of our
study was that not only is early CAV diagnosis at four years
associated with decreased long-time survival, but also that
even mild coronary lesions, scored as CAV grade 1, rep-
resent a negative prognostic factor. Although the majority
of studies are directed to more advanced degrees of CAV,
which are also amenable to interventions, one other recent
report showed that persistent mild coronary lesions have
a negative prognostic impact [2, 21]. This finding em-
phasises the role of preventive measures immediately after
transplantation, before even mild coronary disease may de-
velop.
Limitations of the study
This is a retrospective study, although based on a prospec-
tive cohort. The multivariate analysis of the clinical fac-
tors allows only the finding of associations with CAV, but
not causal relations. Other variables potentially of inter-
est may not have been prospectively collected or analysed.
The study is limited to a single centre, and therefore other
centre-related factors may prevent the generalisation of the
findings.
Conclusion
Our study provides an overview of CAV prevalence and
predictors in the heart transplant recipients in the Nether-
lands. The novel finding is that early CAV grade 1, rep-
resenting mild disease, is associated with decreased long-
term graft survival. We conclude that the management of
CAV should start with donor selection and with preventive
medical treatment according to the guidelines of transplant
care, immediately after heart transplantation.
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